Fenbendazole is an anthelmintic medication that belongs to the benzimidazole class of medicines (i.e., drugs that kill parasitic worms). Mebendazole is another benzimidazole that can be recommended to individuals with specific gastrointestinal illnesses such as threadworms, whipworms, hookworms, and roundworms.

These two medications are frequently mixed up since they both have the same fundamental effect of eradicating parasitic worms. However, fenbendazole for human consumption has not been approved, although mebendazole has been approved for human consumption by regulatory authorities such as the Food and Drug Administration (FDA), whereas fenbendazole is currently only accessible for veterinary usage.

Despite little investigation, researchers have discovered that mebendazole, like fenbendazole, has anti-cancer potential. It prevents worms from absorbing glucose, which they require for growth. Researchers discovered that it can also block cancer cells from receiving glucose, so preventing them from growing.

While fenbendazole for human cancer has gained popularity due to certain fascinating fenbendazole cancer success stories, recent research shows that mebendazole may be more beneficial for treating various types of tumors. Mebendazole, for example, has been demonstrated in tests to be more successful in treating brain, prostate, and ovarian malignancies.